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Treatment of Anorexia and Weight Loss With Megestrol
Acetate in Patients With Cystic Fibrosis
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Summary: Four patients with severe cystic fibrosis lung disease, anorexia and weight loss,
received Megestrol Acetate (MA), as an appetite stimulant. The initial dose was 400–800 mg
daily and was continued for 6–15 months. Appetite was improved, with significant weight gain in
all patients and an increase in their weight for age percentile from <5% at the start of the study
to approximately the 25th percentile after 6 months of use and improvement in quality of life. One
patient discontinued MA after 6 months, and subsequently appetite and weight were depressed.
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INTRODUCTION
Weight loss is a common problem in patients with
advanced cystic fibrosis (CF). 24.4% of patients with CF
fell below the fifth percentile of weight for age in 1996.1
Inadequate weight gain in CF is thought to be due to
energy imbalance related to the increased caloric de-
mands of chronic respiratory disease, and possibly an
elevated metabolic rate compounded by malabsorption
and anorexia.2 With progression of the pulmonary dis-
ease and anorexia, some patients may fail to gain weight
despite methods of nutritional support such as enteral
hyperalimentation through gastrostomy tube feedings.
The suggestion has been made that nutritional interven-
tion is likely to be beneficial when it is begun early in the
development of malnutrition.3
Megestrol acetate (MA), is a synthetic, orally active
derivative of progesterone, which is widely used to treat
advanced breast cancer. A side effect of MA and proges-
terone derivatives in routine therapy is appetite stimula-
tion and weight gain.4 The mechanism by which it stimu-
lates the appetite and causes weight gain is mostly un-
known. It has been postulated that the effect is partly
mediated by neuropeptide Y, a potent central appetite
stimulant.5 In animal models MA stimulates neuropep-
tide Y synthesis, transport and release and this may con-
tribute to its appetite-stimulating effect.6 Several studies
were conducted to evaluate the therapeutic use of MA in
adults with HIV infection and those with cancer.7–10 As
a result, MA was determined to enhance appetite, result-
ing in increased body weight. MA was also evaluated in
children and adolescents with advanced HIV infection
and severe anorexia and was found to be beneficial.11
We present four patients with advanced pulmonary
disease, weight loss and severe anorexia. MA was initi-
ated in these patients to stimulate their appetite. This
appears to be an innovative way of treating these termi-
nally ill patients to improve their nutritional status and
decrease their pulmonary symptoms.
CASE REPORTS
Four children and adolescents with CF (3 females and
1 male) ages 10–18.5 years, received MA in an effort to
stimulate their appetite and improve weight gain. These 4
patients were among the most seriously ill in our center
population. Patients #1, #3 and #4 were prepubertal.
Table 1 summarizes patient characteristics. All patients
had severe lung disease. Three of the four patients had
gastrostomy tubes (GI) placed 1–5 years prior to receiv-
ing MA, at a mean age of 13 ± 4.6 years (SD), with a
range of 7.7–16 years. The fourth patient refused GT
placement. Initial weight gain was noted with the GT
placement and nocturnal calorie supplement. MA was
started at a daily dose of 400–800 mg orally. Weight for
age was less than fifth percentile for all patients at the
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start of MA. Three of the four patients continued MA for
6 months; it was discontinued in patient #1 following a
double lung transplant, patient #2 discontinued MA due
to noncompliance, and patient #3 has been on MA for 15
months, patient #4 has been on MA for 6 months.
RESULTS
All 4 patients were noted to have an increase in appe-
tite and oral intake within days of starting MA; all pa-
tients experienced weight gain. Prior to starting MA, the
first patient was receiving approximately 2,400 kcal/day
mainly from enteral feeding [five cans of two cal HN].
She could not reach her daily caloric needs of 2500–2800
kcal/day secondary to anorexia. Following the start of
MA, her intake increased to 4–5 meals/day plus enteral
feeding and weight gain was noted.
The second patient’s calorie intake/day was 2,250 kcal
from enteral feeding of 4 cans of 2 Cal/min HN formula
plus polycose; his oral intake was negligible. Following
the start of MA his appetite had improved. He continued
to receive enteral feeds, this exceeded his daily require-
ment of 3,300–3,500 kcal.
The third patient was receiving 1920–2400 kcal/day,
mainly through enteral feeding of 4–5 cans of 2 Cal/min
HN. Even though her estimated calorie needs were 2100–
2300 kcal/day, she continued to lose weight. Her appetite
improved after MA was started. She continued enteral
feeding along with 3 meals and 5 snacks/day.
The fourth patient’s calorie intake was 990 kcal/day
prior to starting MA. She did not have a gastrostomy
tube. Her daily requirement was 2,200–2,400 kcal. Fol-
lowing the initiation of MA her calorie intake increased
to exceed her daily requirement. Two months following
MA initiation, she was receiving 2400–2600 kcal/day.
Table 2 summarizes the weight gain over 6 months of
therapy. All patients were less than the fifth percentile
weight for age at the time of starting MA. Six months
later they were at approximately the 25th percentile
weight for age (patient #14 25–50%, patient #2 and #3
4 10–25%, and patient #4 25% weight for age).
Patient 3 who has been on MA for 15 months, has con-
tinued to maintain 10–25% weight for age.
By self report, the well being and quality of life of the
patients improved with the use of MA with decreased
frequency of coughing, decreased sputum production and
increased energy level. Moreover, there were decreases
in the number of pulmonary exacerbations, antibiotic use
and the number of hospitalizations during the study pe-
riod. Pulmonary function testing, chest radiograph scor-
ing12 and clinical scoring13 remained stable with no fur-
ther deterioration. Serum glucose level and glycosylated
hemoglobin were stable with no increase during the
study period.
DISCUSSION
Anorexia and weight loss in advanced CF disease are
due to bronchiectasis, chronic infection and advanced
lung disease. Severe lung disease results in respiratory
failure and accounts for over 90 percent of fatalities.14
Chronic bacterial endobronchitis is associated with an
intense inflammatory response which damages the air-
way and impairs local host-defense mechanisms, result-
ing in progressive lung damage and respiratory failure.15
Weight loss can have significant impact on the physical
and psychological well being of CF patients and can lead
to increased mortality. Dietary intervention through high
calorie diet and supplemental gastrostomy tube feedings
have been widely used in CF patients. However, it is our
observation that with advanced lung disease, some pa-
tients become anorexic and increasing supplemental tube
feedings do not compensate for the increased calorie re-
quirement.
Appetite stimulation can improve the chance that an-
orexic CF patients will increase oral intake to meet their






















1 F 16.6 151.4 <5 43.4 <5 18 12 40
2 M 18.5 180.0 70 49.0 <5 44 15 50
3 F 13.0 142.0 <5 25.6 <5 17 14 45
4 F 10.0 121.0 <5 21.0 <5 22 12 40
Mean 14.4 150.7 34.8 25.3 13.3 43.8
SD 3.6 21.5 13.5 12.7 1.5 4.8
aFEV1, Forced experatory volume at 1 second.
bCXR score, Brasefield CXR score for CF12.




FEV1 Forced expired volume in 1 sec
HN High nutrition
MA Megestrol acetate
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nutritional requirements. MA has been shown to stimu-
late appetite in HIV and cancer patients.5–11 We, there-
fore, initiated MA in four patients once they had exhib-
ited acute weight loss (patients #1, #2, and #3) or
prolonged poor weight gain (patient #4 who refused gas-
trostomy tube placement). The general well being for
these patients improved significantly and the respiratory
symptoms (cough, shortness of breath and sputum pro-
duction) decreased with the use of MA, which in turn,
lead to weight gain in all patients. MA was well tolerated
by all patients. Side effects reported with MA include
hypertension, hyperglycemia, carpal tunnel syndrome,
alopecia, edema, depression and clinical adrenal insuffi-
ciency (fatigue and hypotension).16 None of these side
effects were noted in our patients. However, the number
of subjects in this report is clearly insufficient to draw
conclusions about the likelihood of adverse effects, or the
potential consequences of long term use. To our knowl-
edge, this is the first report of the use of MA in CF
patients for treatment of anorexia and weight loss.
Based on our initial experience, we believe a carefully
designed randomized trial is warranted to establish the
benefits and potential side effects of MA in patients with
advanced CF disease and compromised nutritional status.
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TABLE 2—Summary of Results of Therapy
Patient
No.



















1 43.4 151.4 18 48.4 155.0 20 52.2 159.0 17
2 49.0 180.0 44 56.9 180.0 41 59.5 180.0 37
3 25.6 142.0 17 31.5 146.0 17 38.9 149.0 25
4 21.0 121.0 22 27.2 123.0 32 29.8 125.0 32
Mean 34.8 148.6 25.3 41.0 151.0 27.5 45.1 153.3 27.8
SD 13.5 24.4 12.7 14.0 23.6 11.1 13.3 22.8 8.7
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